Literature DB >> 3012115

Protective effect of monoclonal antibodies on lethal mouse hepatitis virus infection in mice.

K Nakanaga, K Yamanouchi, K Fujiwara.   

Abstract

Neutralizing and nonneutralizing monoclonal antibodies to the peplomer glycoprotein and nucleocapsid protein of a mouse hepatitis virus (MHV), MHV-NuU, protected mice against lethal MHV-2 challenge. Histopathologically, livers of mice receiving protective antibodies showed some focal necrotic lesions with remarkable cellular infiltration instead of fulminant hepatitis caused by MHV-2.

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3012115      PMCID： PMC253053     

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  22 in total

1.  Determination of the protective epitopes on the glycoproteins of Venezuelan equine encephalomyelitis virus by passive transfer of monoclonal antibodies.

Authors:  J H Mathews; J T Roehrig
Journal:  J Immunol       Date:  1982-12       Impact factor: 5.422

Review 2.  The biology and pathogenesis of coronaviruses.

Authors:  H Wege; S Siddell; V ter Meulen
Journal:  Curr Top Microbiol Immunol       Date:  1982       Impact factor: 4.291

3.  Protection against lethal challenge of BALB/c mice by passive transfer of monoclonal antibodies to five glycoproteins of herpes simplex virus type 2.

Authors:  N Balachandran; S Bacchetti; W E Rawls
Journal:  Infect Immun       Date:  1982-09       Impact factor: 3.441

4.  Non-neutralizing monoclonal antibodies can prevent lethal alphavirus encephalitis.

Authors:  A L Schmaljohn; E D Johnson; J M Dalrymple; G A Cole
Journal:  Nature       Date:  1982-05-06       Impact factor: 49.962

Review 5.  The structure and replication of coronaviruses.

Authors:  S Siddell; H Wege; V ter Meulen
Journal:  Curr Top Microbiol Immunol       Date:  1982       Impact factor: 4.291

6.  Use of monoclonal antibodies for analysis of antibody-dependent immunity to ocular herpes simplex virus type 1 infection.

Authors:  J T Rector; R N Lausch; J E Oakes
Journal:  Infect Immun       Date:  1982-10       Impact factor: 3.441

7.  Comparison of mouse hepatitis virus strains for pathogenicity in weanling mice infected by various routes.

Authors:  N Hirano; T Murakami; F Taguchi; K Fujiwara; M Matumoto
Journal:  Arch Virol       Date:  1981       Impact factor: 2.574

8.  Expression of influenza A virus internal antigens on the surface of infected P815 cells.

Authors:  J W Yewdell; E Frank; W Gerhard
Journal:  J Immunol       Date:  1981-05       Impact factor: 5.422

9.  Pathogenesis of mouse hepatitis virus infection. The role of nasal epithelial cells as a primary target of low-virulence virus, MHV-S.

Authors:  F Taguchi; Y Goto; M Aiuchi; T Hayashi; K Fujiwara
Journal:  Microbiol Immunol       Date:  1979       Impact factor: 1.955

10.  Coronaviridae.

Authors:  S G Siddell; R Anderson; D Cavanagh; K Fujiwara; H D Klenk; M R Macnaughton; M Pensaert; S A Stohlman; L Sturman; B A van der Zeijst
Journal:  Intervirology       Date:  1983       Impact factor: 1.763
View more
  65 in total

1.  Production, characterization, and uses of monoclonal antibodies against recombinant nucleoprotein of elk coronavirus.

Authors:  G C Daginakatte; C Chard-Bergstrom; G A Andrews; S Kapil
Journal:  Clin Diagn Lab Immunol       Date:  1999-05

2.  Altering the cellular location of an antigen expressed by a DNA-based vaccine modulates the immune response.

Authors:  P J Lewis; L A Babiuk
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

3.  Control of central nervous system viral persistence by neutralizing antibody.

Authors:  Chandran Ramakrishna; Cornelia C Bergmann; Roscoe Atkinson; Stephen A Stohlman
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

4.  Protection from mouse hepatitis virus type 3-induced acute disease by an anti-nucleoprotein monoclonal antibody. Brief report.

Authors:  J Lecomte; V Cainelli-Gebara; G Mercier; S Mansour; P J Talbot; G Lussier; D Oth
Journal:  Arch Virol       Date:  1987       Impact factor: 2.574

5.  Hemagglutinin-esterase-specific monoclonal antibodies alter the neuropathogenicity of mouse hepatitis virus.

Authors:  K Yokomori; S C Baker; S A Stohlman; M M Lai
Journal:  J Virol       Date:  1992-05       Impact factor: 5.103

6.  Feline coronavirus type II strains 79-1683 and 79-1146 originate from a double recombination between feline coronavirus type I and canine coronavirus.

Authors:  A A Herrewegh; I Smeenk; M C Horzinek; P J Rottier; R J de Groot
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

7.  Effective clearance of mouse hepatitis virus from the central nervous system requires both CD4+ and CD8+ T cells.

Authors:  J S Williamson; S A Stohlman
Journal:  J Virol       Date:  1990-09       Impact factor: 5.103

Review 8.  Long-term humoral immunity against viruses: revisiting the issue of plasma cell longevity.

Authors:  M K Slifka; R Ahmed
Journal:  Trends Microbiol       Date:  1996-10       Impact factor: 17.079

9.  Enhanced virulence mediated by the murine coronavirus, mouse hepatitis virus strain JHM, is associated with a glycine at residue 310 of the spike glycoprotein.

Authors:  Evelena Ontiveros; Taeg S Kim; Thomas M Gallagher; Stanley Perlman
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

10.  MHC class II-restricted T-cell hybridomas recognizing the nucleocapsid protein of avian coronavirus IBV.

Authors:  A M Boots; M J Van Lierop; J G Kusters; P J Van Kooten; B A Van der Zeijst; E J Hensen
Journal:  Immunology       Date:  1991-01       Impact factor: 7.397
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.